| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 10930619 | Cytotherapy | 2014 | 5 Pages | 
Abstract
												Immunosuppressive therapy required to treat an active CD potentially can promote HBV reactivation and worsen liver function. In this study involving a CD case complicated by chronic HBV infection, intensive GMA as a non-pharmacologic treatment intervention was associated with clinical remission and endoscopic improvement without HBV reactivation. Furthermore, GMA was well-tolerated and was without any safety concern. However, suppression of tumor necrosis and interleukin-6by GMA in this clinical setting is potentially very interesting.
											Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Cell Biology
												
											Authors
												Yoko Yokoyama, Ken Fukunaga, Koji Kamikozuru, Toshiyuki Sato, Mikio Kawai, Koji Nogami, Kazuko Nagase, Misaki Nakamura, Masaki Immured, Nobuyuki Hida, Shiro Nakamura, 
											